1. Introduction {#sec1-medicina-56-00014}
===============

Portal hypertension (PHT) is the driving force of clinical progression in patients with liver cirrhosis. Non-selective β-blockers (NSBB), available as propranolol in Taiwan, can effectively reduce PHT by the mechanism of reducing the splanchnic blood flow and lowering the cardiac output \[[@B1-medicina-56-00014]\]. Current practice guidelines recommend the use of NSBB as a primary and secondary prophylaxis strategy for cirrhotic patients with presence of esophageal varices (EV) \[[@B2-medicina-56-00014],[@B3-medicina-56-00014]\]. Villanueva C, et al. \[[@B4-medicina-56-00014],[@B5-medicina-56-00014]\] reported that cirrhotic patients with the development of clinically significant portal hypertension (CSPH) had a greater hepatic vein pressure gradient (HVPG) reduction after NSBB treatment than those without CSPH. NSBB could prevent decompensation in cirrhotic patients with CSPH. Apart from this, many studies focused on the use of NSBB in a decompensated group. Some studies reported that NSBB was not associated with increased mortality among decompensated cirrhotic patients with ascites \[[@B6-medicina-56-00014],[@B7-medicina-56-00014],[@B8-medicina-56-00014],[@B9-medicina-56-00014]\], whereas Kalambokis GN, et al. \[[@B10-medicina-56-00014]\] found that an increased mortality was observed in Child-Pugh C cirrhotic patients with ascites if using NSBB for more than six months. Moreover, NSBB could reduce cancer risk \[[@B11-medicina-56-00014],[@B12-medicina-56-00014]\], including hepatocellular carcinoma (HCC) \[[@B13-medicina-56-00014],[@B14-medicina-56-00014]\]. The issue about the use of NSBB on the prognosis in compensated cirrhotic patients without major complications has seldom been reported.

Therefore, we conducted a large population-based cohort study in a national health care setting in an attempt to clarify the clinical impacts of NSBB on cirrhotic patients without major complications.

2. Methods {#sec2-medicina-56-00014}
==========

2.1. Compliance with Ethical Requirements {#sec2dot1-medicina-56-00014}
-----------------------------------------

The study protocol was approved by the Institutional Review Board and the Ethics Committee of Chang Gung Memorial Hospital at Taoyan in Taiwan (permitted number 201800318B0C503 on 1st April 2019). The Ethics Committee waived the requirement for informed consent for this study, and the data were analyzed anonymously.

2.2. Data Sources {#sec2dot2-medicina-56-00014}
-----------------

The present study analyzed data extracted from the Longitudinal Health Insurance Database 2000 (LHID 2000) of one million individuals (approximately 5% of the entire Taiwan population) who were randomly sampled from the year 2000 Registry for Beneficences of 23.75 million individuals involved in Taiwan's National Health Insurance (NHI) program \[[@B15-medicina-56-00014]\]. Taiwan's National Health Insurance program was initiated in 1995, and covers over 99% of Taiwan's 23 million individuals. LHID 2000 contains the demographic information, diagnostics, medical treatments, prescriptions, and total costs from 1 January 1997 to 31 December 2013.

2.3. Study Cohort, and Inclusion and Exclusion Criteria {#sec2dot3-medicina-56-00014}
-------------------------------------------------------

[Figure 1](#medicina-56-00014-f001){ref-type="fig"} shows a schematic flowchart of the study design. The cohort of patients with liver cirrhosis was identified using ICD-9 CM (International Classification of Diseases, Ninth Revision, Clinical Modification, codes: 571.2, 571.5, or 571.6, based on ≥1 claim of inpatients or ≥2 claims of outpatients in one year and apart ≥28 days) between 1997 and 2013. Patients with ≥18 years old were enrolled in the study. The etiology of cirrhosis was collected, namely: chronic hepatitis B virus (ICD-9 CM codes: 070.2, 070.22, 070.23, 070.3, 070.32, 070.33, and V02.61), chronic hepatitis C virus (ICD-9 CM codes: 070.51, 070.54, and V02.62), and alcohol-related disease (ICD-9 CM codes: 291, 303.0, 303.9, 305.0, 571.0, 571.2, and 571.3). In the present study, we focused on only cirrhotic patients without major complications, and with a later stage of chronic liver disease with the development of portal hypertension. Those who had a diagnosis of spontaneous bacterial peritonitis (SBP; ICD-9-CM code: 567), variceal bleeding (ICD-9-CM codes: 456.8, 456.0, and 456.20), ascites (ICD-9-CM code: 7895, or with frequent abdominal tapping, 54.91, based on ≥3 claims of inpatients in one year or ≥1 claims of admission), jaundice (ICD-9-CM code: 7824), hepato-renal syndrome (ICD-9-CM code: 5724), hepatic coma (ICD-9-CM code: 5722), and other sequelae of chronic liver disease (ICD-9-CM code: 572.8) were defined as having a decompensated status and were excluded from the analyses. Accordingly, patients with cirrhosis without any of the above conditions were considered to have liver cirrhosis without major complications. Those who were \<18 years old, had a history of Human Immunodeficiency Virus (HIV) co-infection (ICD-9-CM codes: 042, 044, and V08), hepatocellular carcinoma (ICD-9-CM code: 155), malignancy other than HCC (ICD-9-CM codes: 140--208, with major illness certificate), loss of medical record for one year, or prior use of PPL before enrollment were also excluded. After propensity score matching, 6896 patients with propranolol exposure and 6896 patients without exposure were analyzed.

2.4. Definition of PPL Exposure {#sec2dot4-medicina-56-00014}
-------------------------------

We defined the exposure of propranolol (ATC code: C07AA05) from the diagnosis of liver cirrhosis to the occurrence of outcomes or to the end of follow-up. To further recognize the possible influence of the dose effect, we adopted the concept of quantifying a prescribed dose of medication, anticipating the average prescription dose per day in adult population, which was known as a cumulative defined daily dose (cDDD) \[[@B16-medicina-56-00014]\]. We classified the propranolol dose into four sets in each group (0, 28, 29--89, and \>90 cDDDs). Patients were considered as not taking any propranolol if the cDDD was zero. Moreover, some concomitant drugs with potential confounding effects, including selective β-blockers (ATC code: C07AB), diuretics (ATC code: C03), thiazides (ATC code: C03A-C) potassium-sparing drugs (ATC code: C03D), and diuretics and potassium-sparing agents in combination (ATC code: C03E) were identified from the index date to the event of interest or to the end of follow-up.

2.5. Study Outcomes {#sec2dot5-medicina-56-00014}
-------------------

The primary outcome was the development of hepatocellular carcinoma. All of the patients were followed from the index date to the event of interest, or to the end of the three-year follow-up. The secondary outcome was spontaneous bacterial peritonitis, all-cause mortality, liver transplantation (ICD9 code: V42.7), or any diagnosis indicative of decompensation, which is defined as above.

2.6. Confounder Assessment {#sec2dot6-medicina-56-00014}
--------------------------

The patients' underlying comorbid conditions were identified within one year prior to the index date. The burden of comorbid illness was assessed based on the Deyo modification of the Charlson comorbidity index (CCI), which has been shown to be a well-validated measure of comorbidity, adjusting for disease burden in the administrative data \[[@B17-medicina-56-00014]\]. To better understand the comorbid illness on the confounding impact on the development of HCC, the burden of comorbid illness was further separately discussed.

Other potential risk factors, including the liver disease treatment (statins (atorvastatin ATC codes: C10AA05, C10BX08, C10BX03, C10BA05, C10BX12, C10BX06, and C10BX11; fluvastatin ATC code: C10AA04; pitavastatin ATC code: C10AA08; rosuvastatin ATC codes: C10AA07, C10BX05, 10BX09, C10BA06, C10BX10, and C10BX07; simvastatin ATC codes: C10AA01, C10BX01, C10BA02, C10BA04, C10BX04, and A10BH51) \[[@B18-medicina-56-00014],[@B19-medicina-56-00014]\], lipid-lowering agents (clofibrate ATC code: C10AB01; bezafibrate ATC code: C10AB02; gemfibrozil ATC code: C10AB04; fenofibrate ATC code: C10AB05; nicotinic acid ATC code: C04AC01; and acipimox ATC code: C10AD06), angiotensin converting-enzyme inhibitor (captopril ATC code: C09AA01; lisinopril ATC code: C09AA03; perindopril ATC code: C09AA04; ramipril ATC code: C09AA05; quinapril ATC code: C09AA06; benazepril ATC code: C09AA07; cilazapril ATC code: C09AA08; and fosinopril ATC code: C09AA09), aspirin (ATC code: B01AC06), metformin (ATC code: A10BA02), diuretics (furosemide ATC code: C03CA01, C02LA01; spironolactone ATC code: C03DA01), and selective β-blockers (ATC code: C07AB)), were assessed in the study. Only patients with drug use for at least 28 days within one year prior to the index hospitalization, or use for at least 28 days during the study follow-up were analyzed.

2.7. Statistical Analysis {#sec2dot7-medicina-56-00014}
-------------------------

We performed a matched case control study by using propensity score adjustment with immortal time, sex, age group, CCI, HTN, and prior medication (interferon, metformin, aspirin, angiotensin converting-enzyme inhibitor, lipid lowering drugs, statins, diuretics, and selective beta blockers). Continuous data were presented as means ± standard deviation (SD), and categorical data were presented as frequencies and percentages. Pearson's chi-square or Fisher's exact two-tailed tests were used for the analysis of categorical data, while continuous variables were analyzed using the t-test, where appropriate.

To assess the impact of the competing risk of death during the index hospitalization on the outcome prediction, the standard and cause-specific approach of the Cox proportional hazard model was employed to estimate the relative hazard ratio of an outcome event. Adjustments of patient demographics, clinical conditions, and medication usage were made in the regression model. The Kaplan--Meier method with the log-rank test was employed to compare the cumulative incidence between comparison groups. Two-tailed *p*-values of \<0.05 were considered statistically significant. All of the statistical analyses were conducted using SAS version 9.4 (SAS Institute's Inc., Cary, NC, USA, 2013).

3. Results {#sec3-medicina-56-00014}
==========

3.1. Patient Characteristics {#sec3dot1-medicina-56-00014}
----------------------------

The baseline characteristics of the parameters before matching are presented in [Supplementary Table S1](#app1-medicina-56-00014){ref-type="app"}. [Table 1](#medicina-56-00014-t001){ref-type="table"} shows the demographic data for the two groups after propensity score adjustment, which included the etiologies of liver cirrhosis, such as hepatitis B virus infection, hepatitis C virus infection, and alcoholism.

3.2. Outcomes of Spontaneous Bacterial Peritonitis and Assessments of Risk Factors {#sec3dot2-medicina-56-00014}
----------------------------------------------------------------------------------

As shown in [Table 2](#medicina-56-00014-t002){ref-type="table"}, patients with propranolol exposure had significantly higher rates of spontaneous bacterial peritonitis (1.42% vs. 0.75%, *p* = 0.0002) during the three-year follow-up period (log-rank *p* = 0.0177, shown in [Figure 2](#medicina-56-00014-f002){ref-type="fig"}) and for ascites (4.32% vs. 0.64%, *p* \< 0.0001). No significant difference was observed with respect to hepatorenal syndrome (0.26% vs. 0.15%, *p* = 0.1302).

As shown in [Table 3](#medicina-56-00014-t003){ref-type="table"}, male gender (aHR: 1.90, 95% CI: 1.30\~5.76, *p* = 0.0008), aged ≥65 (aHR: 2.02, 95% CI: 1.08\~3.75, *p* = 0.0270), and concomitant diuretic usage (aHR: 8.56, 95% CI: 5.93\~12.37, *p* \< 0.0001) were independent risk factors for the development of SBP on the multivariate analysis. On the contrary, the concomitant use of selective β-blockers was a protective factor from SBP (aHR: 0.35, 95% CI: 0.19\~0.67, *p* = 0.0014). Notably, there was no significant impact on the development of SBP about the exposure of propranolol or not (aHR: 1.24, 95% CI: 0.88\~1.75; *p* = 0.2111).

3.3. All-Cause Mortality {#sec3dot3-medicina-56-00014}
------------------------

During the three-year follow-up period, cirrhotic patients without major complications, who had PPL exposure for more than 90 days, had a significantly lower rate of all-cause mortality than those without exposure. Notably, those who had exposure between 1\~28 days and 29\~90 days had a higher all-cause mortality rate ([Figure 3](#medicina-56-00014-f003){ref-type="fig"}).

As shown in [Table 4](#medicina-56-00014-t004){ref-type="table"}, on the multivariate analysis, male gender (aHR: 1.59, 95% CI: 1.38\~1.83, *p* \< 0.0001), an aged condition (35--49 aHR: 1.73, 95% CI: 1.34\~2.21; 50--64 aHR: 2.63, 95% CI: 2.04\~3.40; ≥65 aHR: 5.07, 95% CI: 3.89\~6.61, *p* \< 0.0001), peripheral vascular disease (aHR: 3.15, 95% CI: 1.67\~5.93, *p* = 0.0004), cerebrovascular disease (aHR: 1.56, 95% CI: 1.20\~2.01, *p* = 0.0008), dementia (aHR: 1.86, 95% CI: 1.04\~3.32, *p* = 0.0350), pulmonary disease (aHR: 1.25, 95% CI: 1.03\~1.52, *p* = 0.0218), peptic ulcer (aHR: 1.29, 95% CI: 1.11\~1.50, *p* = 0.0009), renal disease (aHR: 1.87, 95% CI: 1.42\~2.48, *p* \< 0.0001), baseline (aHR: 1.88, 95% CI: 1.45\~2.44, *p* \< 0.0001), and concomitant diuretics (aHR: 2.69, 95% CI: 2.33\~3.11, *p* \< 0.0001) were independent risk factors of all-cause mortality. Baseline Angiotensin-converting enzyme inhibitor ACEI (aHR: 0.71, 95% CI: 0.52\~0.97, *p* = 0.0307) and concomitant selective beta blockers (aHR: 0.44, 95% CI: 0.35\~0.56, *p* \< 0.0001) were protective factors. As for propranolol, a trend from a harmful effect if cDDD was \<90 days (1\~28 cDDD, aHR: 1.33, 95% CI: 1.15\~1.53, *p* = 0.0001; 29\~90 cDDD, aHR: 1.12, 95% CI: 0.91\~1.40, *p* = 0.2888), to a protective effect if cDDD was more than 90 days (aHR: 0.79, 95% CI: 0.64\~0.98, *p* = 0.0340) was observed.

3.4. Outcomes of Hepatocellular Carcinoma and Assessments of Risk Factors {#sec3dot4-medicina-56-00014}
-------------------------------------------------------------------------

In the multivariate analysis, the independent risk factors of HCC development were gender (aHR: 1.47, 95% CI: 1.20\~1.79, *p* = 0.0002), aging (35--49 aHR: 3.33, 95% CI: 2.02\~5.49; 50--64 aHR: 7.67, 95% CI: 4.68\~12.55; ≥65 aHR: 10.72, 95% CI: 6.43\~17.88, *p* \< 0.0001), and concomitant use of diuretics (aHR: 5.65, 95% CI: 4.61\~6.92, *p* \< 0.0001). The concomitant use of selective beta blockers was a protective factor (aHR: 0.54, 95% CI: 0.39\~0.74, *p* = 0.0001).

As for propranolol, the cirrhotic patients without major complications had an increased protective effect free from the development of HCC when they had an increased cDDD of propranolol exposure ([Figure 4](#medicina-56-00014-f004){ref-type="fig"} and [Table 5](#medicina-56-00014-t005){ref-type="table"}). The protective effect was even more significant among those with propranolol exposure for more than 90 days when compared with those without propranolol exposure (aHR: 0.49, 95% CI: 0.36\~0.67, *p* \< 0.0001).

4. Discussions {#sec4-medicina-56-00014}
==============

Clinically significant portal hypertension was defined as a hepatic venous pressure gradient (HVPG) of ≥10 mmHg. Compensated cirrhotic patients with CSPH may present with the appearance of varices and a risk of decompensation \[[@B20-medicina-56-00014],[@B21-medicina-56-00014]\]. Owning to the development of hyperdynamic circulation in cirrhotic patients with CSPH, NSBB could effectively reduce HVPG, and hence improve the clinical outcomes, including bleeding and mortality \[[@B22-medicina-56-00014]\]. On the contrary, compensated cirrhotic patients without CSPH were not suggested the use of NSBB because of the lack of development of hyperdynamic circulation. This current study focused on patients with a diagnosis of cirrhosis, and excluded any diagnosis of decompensation, which meant that we enrolled cirrhotic patients without CSPH clinically. We found that patients with PPL exposure had significantly higher rates of decompensation events than those without PPL ([Table 2](#medicina-56-00014-t002){ref-type="table"}). It did not mean that PPL caused worse outcomes among cirrhotic patients without CSPH. As shown in [Table 1](#medicina-56-00014-t001){ref-type="table"}, patients with propranolol exposure still had more comorbidity than those without exposure, even after propensity score matching adjustment. The bottom line was that, in real world practice, the clinical physicians prescribed propranolol to patients with a more serious clinical condition, including a higher trend toward CSPH and decompensations events. The use of NSBB was not helpful in preventing further progress of decompensation among cirrhotic patients without CSPH ([Supplementary Figure S1](#app1-medicina-56-00014){ref-type="app"} and [Supplementary Table S2](#app1-medicina-56-00014){ref-type="app"}).

Most cirrhotic patients suffered from death after the development of decompensation. Many studies focused on the discussion of the safety concerns of NSBB use among decompensated cirrhotic patients, especially with presence of ascites, but they have not been conclusive to date \[[@B6-medicina-56-00014],[@B7-medicina-56-00014],[@B8-medicina-56-00014],[@B9-medicina-56-00014],[@B10-medicina-56-00014]\]. The NSBB might not affect the mortality, but should be used cautiously, especially among enrolled patients with a history of spontaneous bacterial peritonitis \[[@B23-medicina-56-00014]\]. On the contrary, non-liver-related diseases were predominant causes of mortality among compensated cirrhotic patients \[[@B24-medicina-56-00014],[@B25-medicina-56-00014]\]. Similarly, the current study showed that host factors (male gender and aged condition) and comorbidity (peripheral vascular disease, cerebrovascular disease, dementia, pulmonary disease, and renal disease) were the independent risk factors of mortality. Moreover, a protective effect from mortality was observed among patients with NSBB exposure for more than 90 days cDDD (aHR: 0.79, 95% CI: 0.64\~0.98, *p* = 0.0340). Brito-Azevedo A, et al. reported that improving endothelial function was detected among compensated cirrhotic patients receiving PPL compared with those without propranolol use (propranolol users, n = 6, 567 ± 377% vs. non-propranolol users, n = 14, 490 ± 188%; *p* = 0.01) \[[@B26-medicina-56-00014]\]. Moreover, propranolol could reduce inflammation by decreasing intestinal permeability, bacterial translocation, and serum levels of IL-6 \[[@B27-medicina-56-00014],[@B28-medicina-56-00014]\], and therefore might explain the dose-dependent effect of PPL on the impact of mortality.

Ripoll C, et al. reported that cirrhotic patients with CSPH had a higher annual incidence of HCC than those without CSPH (2.1% vs. 0.35%) \[[@B29-medicina-56-00014]\]. Furthermore, propranolol had anti-cancer effects and could block the β-2 adrenergic receptor (ADRB2), whose expression was upregulated in HCC \[[@B30-medicina-56-00014]\]. A meta-analysis by Thiele M, et al. reported that NSBB may prevent HCC in patients with cirrhosis \[[@B14-medicina-56-00014]\]. However, those trials enrolled in this meta-analysis were not targeted for the survey of NSBB and HCC. Herrera l, et al. performed a retrospective cohort study including 73 patients treated with NSBB and 100 patients without NSBB use, and found that a lower cumulative incidence of HCC during five or ten years of follow-up was observed among propranolol users. It was reported that increasing the protective effect from the development of HCC was observed among patients with propranolol users (1\~28 cDDD aHR: 0.81→29\~90 cDDD aHR: 0.80→\>90 cDDD aHR: 0.49, as shown in [Table 5](#medicina-56-00014-t005){ref-type="table"}) compared with those without exposure. The strength of this study was that it was a large sample size population-based study. To our knowledge, it is the first study to demonstrate the quantification of PPL exposure to the association of HCC among cirrhotic patients without CSPH.

Increased vascular resistance was the predominant mechanism of PHT in the early phase of cirrhosis. Carvedilol could decrease the vascular resistance by its intrinsic vasodilator activity, and was reported to be more effective in reducing PHT than propranolol \[[@B31-medicina-56-00014],[@B32-medicina-56-00014]\]. Current practice guidelines recommend carvedilol as the choice of primary prevention for cirrhotic patients with esophageal varices \[[@B2-medicina-56-00014]\]. In this study, we found that patients with a concomitant use of selective BB had beneficial effects for the prevention of SBP, better survival rates, and lower rates of HCC development. For patients with intolerances or non-responders to NSBB, carvedilol might be a promising therapy for compensated cirrhotic patients without CSPH.

This study has several limitations. First, to select compensated cirrhotic patients without CSPH, we performed rigorous exclusions of the diagnosis supportive of decompensation clinically. We could only define the study cohort as a majority of patients with compensated cirrhosis without major complications, but not as compensated patients without CSPH. Non-invasive exams highly suggestive of CSPH, including liver stiffness (≥20--25 kPa by transient elastography) \[[@B33-medicina-56-00014]\] or the detection of porto-systemic shunting or varices \[[@B3-medicina-56-00014],[@B33-medicina-56-00014]\] should be collected in future studies. Second, we could not accurately classify the patients clinically because of the lack of hemodynamics and laboratory data. Propensity score matching adjustment was performed for the correction of potential confounding factors. Third, the actual dose of PPL and the duration were not available from the NHIRD. In this current study, a positive dose-response effect of PPL on the prevention of HCC by using the concept of cDDD was observed. Based on this important finding, a prospective study focused on the dose and the duration of PPL use among compensated cirrhotic patients without CSPH should be further clarified.

In conclusion, the current study suggested that high cumulative doses of propranolol could decreased the risk of hepatocellular carcinoma among compensated cirrhotic patients without major complications. Further large-scale prospective studies are still required to confirm the finding in this study.
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###### 

Patient's characteristics after propensity score matching adjustment.

  Variable                                                                    Exposure   Non-Exposure                                          
  --------------------------------------------- ----------------------------- ---------- -------------- --------- --------- --------- -------- ----------
  **Total**                                     13,792                        6896       (50.00)        6896      (50.00)                      
  **Sex**                                                                                                                             0.8196   
                                                Female                        5237       2625           (38.07)   2612      (37.88)   0.00     
                                                Male                          8555       4271           (61.93)   4284      (62.12)   0.00     
  **Age group**                                                                                                             0.01      0.7577   
                                                18--34                        3254       1609           (23.33)   1645      (23.85)            
                                                35--49                        5463       2722           (39.47)   2741      (39.75)            
                                                50--64                        3461       1755           (25.45)   1706      (24.74)            
                                                65+                           1614       810            (11.75)   804       (11.66)            
  **Covariate**                                                                                                                                
                                                Acute myocardial infarction   12         9              (0.13)    3         (0.04)    0.03     0.0831
                                                Congestive heart failure      111        67             (0.97)    44        (0.64)    0.04     0.0284
                                                Peripheral vascular disease   32         18             (0.26)    14        (0.20)    0.01     0.4790
                                                Cerebral vascular accident    369        184            (2.67)    185       (2.68)    0.00     0.9579
                                                Dementia                      37         20             (0.29)    17        (0.25)    0.01     0.6214
                                                Pulmonary disease             876        449            (6.51)    427       (6.19)    0.01     0.4424
                                                Connective tissue disorder    99         52             (0.75)    47        (0.68)    0.01     0.6140
                                                Peptic ulcer                  2194       1113           (16.14)   1081      (15.68)   0.01     0.4563
                                                Liver cirrhosis               3447       1964           (28.48)   1483      (21.51)            \<0.0001
                                                Hepatitis B Virus             7885       3605           (52.28)   4280      (62.06)            \<0.0001
                                                Hepatitis C Virus             3079       1653           (23.97)   1426      (20.68)            \<0.0001
                                                Alcohol                       3544       2159           (31.31)   1385      (20.08)            \<0.0001
                                                Diabetes                      920        485            (7.03)    435       (6.31)    0.03     0.0879
                                                Diabetes complications        189        115            (1.67)    74        (1.07)    0.05     0.0027
                                                Paraplegia                    36         18             (0.26)    18        (0.26)    0.00     1.0000
                                                Renal disease                 250        139            (2.02)    111       (1.61)    0.03     0.0739
                                                Severe liver disease          3          2              (0.03)    1         (0.01)    0.01     0.5637
                                                Hypertension                  1969       1032           (14.97)   937       (13.59)   0.04     0.0208
  **Prior medications**                                                                                                                        
  **Interferon-based therapy**                                                                                                                 
                                                interferon                    43         23             (0.33)    20        (0.29)    0.01     0.6468
  **Metformin**                                 605                           328        (4.76)         277       (4.02)    0.04      0.0340   
  **Aspirin**                                   520                           286        (4.15)         234       (3.39)    0.04      0.0201   
  **Angiotensin converting-enzyme inhibitor**   376                           200        (2.90)         176       (2.55)    0.02      0.2095   
                                                Captopril                     136        70             (1.02)    66        (0.96)             0.7303
                                                Lisinopril                    63         35             (0.51)    28        (0.41)             0.3767
                                                Perindopril                   51         25             (0.36)    26        (0.38)             0.8884
                                                Ramipril                      42         23             (0.33)    19        (0.28)             0.5365
                                                Quinapril                     26         13             (0.19)    13        (0.19)             1.0000
                                                Benazepril                    3          2              (0.03)    1         (0.01)             0.5637
                                                Cilazapril                    17         8              (0.12)    9         (0.13)             0.8082
                                                Fosinopril                    62         36             (0.52)    26        (0.38)             0.2031
  **Lipid lowering drugs**                      222                           129        (1.87)         93        (1.35)    0.04      0.0149   
                                                Clofibrate                                                                                     0.0149
                                                Bezafibrate                   30         13             (0.19)    17        (0.25)             0.4647
                                                Gemfibrozil                   129        78             (1.13)    51        (0.74)             0.0169
                                                Fenofibrate                   74         44             (0.64)    30        (0.44)             0.1027
                                                Nicotinic acid                4          2              (0.03)    2         (0.03)             1.0000
                                                Acipimox                      7          6              (0.09)    1         (0.01)             0.0587
  **Statins**                                   81                            48         (0.70)         33        (0.48)    0.03      0.0946   
                                                Atorvastatin                                                                                   0.0946
                                                Fluvastatin                   47         26             (0.38)    21        (0.30)             0.4650
                                                Pitavastatin                                                                                   0.4650
                                                Rosuvastatin                  30         19             (0.28)    11        (0.16)             0.1437
                                                Simvastatin                   7          5              (0.07)    2         (0.03)             0.2567
  **Diuretics**                                 272                           145        (2.10)         127       (1.84)    0.02      0.2703   
                                                Furosemide                    233        125            (1.81)    108       (1.57)             0.2613
                                                Spironolactone                75         36             (0.52)    39        (0.57)             0.7283
  **Selective beta blockers**                   577                           293        (4.25)         284       (4.12)    0.01      0.7019   
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###### 

Outcomes between the two groups. HCC---hepatocellular carcinoma.

  Variable                                  N        Exposure   Non-Exposure   *p*-Value             
  ----------------------------------------- -------- ---------- -------------- ----------- --------- ----------
  **Total**                                 13,792   6896       (50.00)        6896        (50.00)   
  Spontaneous bacterial peritonitis         150      98         (1.42)         52          (0.75)    0.0002
  Decompensation                            546      396        (5.74)         150         (2.18)    \<0.0001
  Hepatorenal syndrome                      28       18         (0.26)         10          (0.15)    0.1302
  Other sequelae of chronic liver disease   41       29         (0.42)         12          (0.17)    0.0078
  Ascites                                   342      298        (4.32)         44          (0.64)    \<0.0001
  Jaundice                                  75       54         (0.78)         21          (0.30)    0.0001
  Hepatic coma                              294      191        (2.77)         103         (1.49)    \<0.0001
  Variceal bleeding                         260      197        (2.86)         63          (0.91)    \<0.0001
  All-cause mortality                       966      577        (8.37)         389         (5.64)    \<0.0001
  Liver transplantation                     21       6          (0.09)         15          (0.22)    0.0494
  HCC                                       462      232        (3.36)         230         (3.34)    0.9246
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###### 

Factors associated with spontaneous bacterial peritonitis. CCI---Charlson comorbidity index.

  Variable                                   Adjusted HR   95% CI   *p*-Value   
  ------------------------------------------ ------------- -------- ----------- ----------
  **Sex**                                                                       
   Male vs. female                           1.90          (1.30)   (2.76)      0.0008
  **Age Group**                                                                 
   18--34                                                                       
   35--49                                    1.15          (0.66)   (2.00)      0.6204
   50--64                                    1.34          (0.74)   (2.40)      0.3307
   65+                                       2.02          (1.08)   (3.75)      0.0270
  **Covariate**                                                                 
  **CCI**                                                                       
   Congestive heart failure                  1.98          (0.76)   (5.11)      0.1603
   Peripheral vascular disease               2.98          (0.41)   (21.83)     0.2819
   Cerebral vascular accident                0.53          (0.18)   (1.61)      0.2657
   Pulmonary disease                         0.92          (0.52)   (1.63)      0.7716
   Peptic ulcer                              1.27          (0.86)   (1.88)      0.2279
   Liver cirrhosis                           1.02          (0.69)   (1.49)      0.9260
   Diabetes                                  1.17          (0.61)   (2.24)      0.6318
   Diabetes complications                    0.57          (0.17)   (1.90)      0.3612
   Paraplegia                                4.72          (0.55)   (40.53)     0.1570
   Renal disease                             1.63          (0.70)   (3.80)      0.2605
   Hypertension                              0.71          (0.43)   (1.18)      0.1845
  **Baseline Medications**                                                      
   Metformin                                 1.41          (0.67)   (2.95)      0.3676
   Aspirin                                   0.45          (0.17)   (1.15)      0.0949
   Angiotensin converting-enzyme inhibitor   0.82          (0.34)   (2.01)      0.6670
   Lipid lowering drugs                      1.10          (0.35)   (3.52)      0.8688
   Diuretics                                 1.83          (0.96)   (3.47)      0.0652
   Selective beta blockers                   0.83          (0.34)   (2.04)      0.6904
  **Concomitant Medications**                                                   
   Selective beta blockers                   0.35          (0.19)   (0.67)      0.0014
   Diuretics                                 8.56          (5.93)   (12.37)     \<0.0001
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###### 

Factors associated with all-cause mortality.

  Variable                                   Adjusted HR   95% CI   *p*-Value   
  ------------------------------------------ ------------- -------- ----------- ----------
  **Propranolol Exposure**                                                      
   **1\~28 Days vs. non-exposure**           1.33          (1.15)   (1.53)      0.0001
   **29\~90 Days vs. non-exposure**          1.12          (0.91)   (1.40)      0.2888
   **\>90 Days vs. non-exposure**            0.79          (0.64)   (0.98)      0.0340
  **Sex**                                                                       
   Male vs. female                           1.59          (1.38)   (1.83)      \<0.0001
  **Age Group**                                                                 
   18--34                                                                       
   35--49                                    1.73          (1.34)   (2.21)      \<0.0001
   50--64                                    2.63          (2.04)   (3.40)      \<0.0001
   65+                                       5.07          (3.89)   (6.61)      \<0.0001
  **Covariate**                                                                 
  **CCI**                                                                       
   Acute myocardial infarction               2.27          (0.89)   (5.82)      0.0870
   Congestive heart failure                  1.37          (0.95)   (1.97)      0.0914
   Peripheral vascular disease               3.15          (1.67)   (5.93)      0.0004
   Cerebral vascular accident                1.56          (1.20)   (2.01)      0.0008
   Dementia                                  1.86          (1.04)   (3.32)      0.0350
   Pulmonary disease                         1.25          (1.03)   (1.52)      0.0218
   Connective tissue disorder                0.49          (0.16)   (1.51)      0.2133
   Peptic ulcer                              1.29          (1.11)   (1.50)      0.0009
   Liver cirrhosis                           0.78          (0.67)   (0.92)      0.0025
   Diabetes                                  1.17          (0.92)   (1.50)      0.2098
   Diabetes complications                    1.21          (0.85)   (1.72)      0.2872
   Paraplegia                                0.75          (0.31)   (1.79)      0.5116
   Renal disease                             1.87          (1.42)   (2.48)      \<0.0001
   Severe liver disease                      1.61          (0.22)   (11.63)     0.6392
   Hypertension                              1.06          (0.89)   (1.27)      0.5056
  **Baseline Medications**                                                      
   Metformin                                 1.16          (0.87)   (1.55)      0.3157
   Aspirin                                   0.84          (0.65)   (1.09)      0.1964
   Angiotensin converting-enzyme inhibitor   0.71          (0.52)   (0.97)      0.0307
   Lipid lowering drugs                      0.80          (0.48)   (1.32)      0.3820
   Statins                                   0.91          (0.40)   (2.04)      0.8147
   Diuretics                                 1.88          (1.45)   (2.44)      \<0.0001
   Selective beta blockers                   0.94          (0.70)   (1.26)      0.6631
  **Concomitant Medications**                                                   
   Selective beta blockers                   0.44          (0.35)   (0.56)      \<0.0001
   Diuretics                                 2.69          (2.33)   (3.11)      \<0.0001
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###### 

Factors associated with hepatocellular carcinoma.

  Variable                                   Adjusted HR                   95% CI   *p*-Value              
  ------------------------------------------ ----------------------------- -------- ----------- ---------- ----------
  **Propranolol Exposure**                                                                                 
   **1\~28 Days vs. non-exposure**           0.81                          (0.65)   (1.01)      0.0580     
   **29\~90 Days vs. non-exposure**          0.80                          (0.58)   (1.09)      0.1588     
   **\>90 Days vs. non-exposure**            0.49                          (0.36)   (0.67)      \<0.0001   
  **Sex**                                                                                                  
   Male vs. female                           1.47                          (1.20)   (1.79)      0.0002     
  **Age Group**                                                                                            
   18--34                                                                                                  
   35--49                                    3.33                          (2.02)   (5.49)      \<0.0001   
   50--64                                    7.67                          (4.68)   (12.55)     \<0.0001   
   65+                                       10.72                         (6.43)   (17.88)     \<0.0001   
  **Covariate**                                                                                            
  **CCI**                                                                                                  
   1                                         Acute myocardial infarction   1.82     (0.25)      (13.18)    0.5552
   2                                         Congestive heart failure      0.98     (0.45)      (2.10)     0.9489
   3                                         Peripheral vascular disease   0.74     (0.10)      (5.26)     0.7597
   4                                         Cerebral vascular accident    0.78     (0.46)      (1.33)     0.3695
   6                                         Pulmonary disease             0.79     (0.57)      (1.10)     0.1584
   7                                         Connective tissue disorder    0.64     (0.16)      (2.58)     0.5294
   8                                         Peptic ulcer                  1.03     (0.82)      (1.30)     0.7978
   9                                         Liver cirrhosis               1.46     (1.19)      (1.78)     0.0002
   10                                        Diabetes                      0.75     (0.51)      (1.10)     0.1362
   11                                        Diabetes complications        1.10     (0.62)      (1.96)     0.7375
   12                                        Renal disease                 0.90     (0.47)      (1.71)     0.7458
   13                                        Hypertension                  0.49     (0.37)      (0.66)     \<0.0001
  **Baseline Medications**                                                                                 
   Metformin                                 2.08                          (1.40)   (3.08)      0.0003     
   Aspirin                                   0.71                          (0.46)   (1.11)      0.1355     
   Angiotensin converting-enzyme inhibitor   1.23                          (0.80)   (1.90)      0.3513     
   Lipid lowering drugs                      0.50                          (0.20)   (1.21)      0.1248     
   Statins                                   1.30                          (0.41)   (4.09)      0.6527     
   Diuretics                                 0.74                          (0.44)   (1.24)      0.2547     
   Selective beta blockers                   1.21                          (0.78)   (1.87)      0.3858     
  **Concomitant Medications**                                                                              
   Selective beta blockers                   0.54                          (0.39)   (0.74)      0.0001     
   Diuretics                                 5.65                          (4.61)   (6.92)      \<0.0001   
